Trevi Therapeutics Ownership 2024 | Who Owns Trevi Therapeutics Now?
Institutional Ownership
5.99%
Insider Ownership
1.25%
Retail Ownership
92.77%
Institutional Holders
29.00
Trevi Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| NEA MANAGEMENT COMPANY, LLC | 11.43% | 2.55% | 11,370,376 | - | - | 33,883,720 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 7.42% | 1.03% | 7,381,090 | - | - | 21,995,648 | Jun 30, 2024 |
| RUBRIC CAPITAL MANAGEMENT LP | 5.05% | 0.39% | 5,026,931 | -537,192 | -9.65% | 14,980,254 | Jun 30, 2024 |
| VIKING GLOBAL INVESTORS LP | 4.42% | 0.05% | 4,400,000 | - | - | 13,112,000 | Jun 30, 2024 |
| VR ADVISER, LLC | 3.44% | 0.65% | 3,422,637 | -38 | -0.00% | 10,199,458 | Jun 30, 2024 |
| BLACKROCK INC. | 3.15% | 0.00% | 3,135,115 | 759,406 | 31.97% | 9,342,643 | Jun 30, 2024 |
| LOGOS GLOBAL MANAGEMENT LP | 2.81% | 0.68% | 2,800,000 | 600,000 | 27.27% | 8,344,000 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 2.66% | 1.80% | 2,645,000 | - | - | 7,882,100 | Jun 30, 2024 |
| VANGUARD GROUP INC | 2.45% | 0.00% | 2,437,451 | 133,803 | 5.81% | 7,263,603 | Jun 30, 2024 |
| BIOIMPACT CAPITAL LLC | 1.52% | 0.70% | 1,510,174 | 169,214 | 12.62% | 4,500,319 | Jun 30, 2024 |
| ALLY BRIDGE GROUP (NY) LLC | 1.48% | 2.62% | 1,474,926 | 1,474,926 | 100.00% | 4,395,279 | Jun 30, 2024 |
| ROSALIND ADVISORS, INC. | 1.40% | 3.19% | 1,391,577 | 465,561 | 50.28% | 4,146,899 | Jun 30, 2024 |
| MAI CAPITAL MANAGEMENT | 1.32% | 0.04% | 1,318,496 | 186,675 | 16.49% | 3,929,118 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.15% | 0.00% | 1,146,748 | 248,783 | 27.71% | 3,417,619 | Jun 30, 2024 |
| STATE STREET CORP | 0.90% | 0.00% | 899,861 | 101,612 | 12.73% | 2,681,586,000 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.85% | 0.59% | 844,235 | - | - | 2,515,820 | Jun 30, 2024 |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 0.61% | 0.15% | 605,442 | -134,686 | -18.20% | 1,804,217 | Jun 30, 2024 |
| CHECKPOINT CAPITAL L.P. | 0.50% | 0.90% | 500,089 | -5,993 | -1.18% | 1,490,265 | Jun 30, 2024 |
| TEJARA CAPITAL LTD | 0.41% | 0.44% | 405,988 | 368,507 | 983.18% | 1,209,844 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.32% | 0.00% | 321,102 | -6,590 | -2.01% | 956,884,000 | Jun 30, 2024 |
Trevi Therapeutics's largest institutional shareholder is NEA MANAGEMENT COMPANY, LLC, holding 11.43% of the company's total share outstanding, currently valued at $33.88M. The top 10 institutional shareholders own together 44.34% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ROSALIND ADVISORS, INC. | 1.40% | 3.19% | 1,391,577 | 465,561 | 50.28% | 4,146,899 | Jun 30, 2024 |
| ALLY BRIDGE GROUP (NY) LLC | 1.48% | 2.62% | 1,474,926 | 1,474,926 | 100.00% | 4,395,279 | Jun 30, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 11.43% | 2.55% | 11,370,376 | - | - | 33,883,720 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 2.66% | 1.80% | 2,645,000 | - | - | 7,882,100 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 7.42% | 1.03% | 7,381,090 | - | - | 21,995,648 | Jun 30, 2024 |
| CHECKPOINT CAPITAL L.P. | 0.50% | 0.90% | 500,089 | -5,993 | -1.18% | 1,490,265 | Jun 30, 2024 |
| BIOIMPACT CAPITAL LLC | 1.52% | 0.70% | 1,510,174 | 169,214 | 12.62% | 4,500,319 | Jun 30, 2024 |
| LOGOS GLOBAL MANAGEMENT LP | 2.81% | 0.68% | 2,800,000 | 600,000 | 27.27% | 8,344,000 | Jun 30, 2024 |
| ACUTA CAPITAL PARTNERS, LLC | 0.26% | 0.65% | 260,000 | 260,000 | 100.00% | 774,800 | Jun 30, 2024 |
| VR ADVISER, LLC | 3.44% | 0.65% | 3,422,637 | -38 | -0.00% | 10,199,458 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.85% | 0.59% | 844,235 | - | - | 2,515,820 | Jun 30, 2024 |
| PROPEL BIO MANAGEMENT, LLC | 0.26% | 0.50% | 260,000 | - | - | 774,800 | Jun 30, 2024 |
| TEJARA CAPITAL LTD | 0.41% | 0.44% | 405,988 | 368,507 | 983.18% | 1,209,844 | Jun 30, 2024 |
| RUBRIC CAPITAL MANAGEMENT LP | 5.05% | 0.39% | 5,026,931 | -537,192 | -9.65% | 14,980,254 | Jun 30, 2024 |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 0.61% | 0.15% | 605,442 | -134,686 | -18.20% | 1,804,217 | Jun 30, 2024 |
| PFS PARTNERS, LLC | 0.08% | 0.15% | 79,000 | -20,000 | -20.20% | 235,420 | Jun 30, 2024 |
| WEALTHTRUST AXIOM LLC | 0.06% | 0.06% | 63,500 | - | - | 189,230 | Jun 30, 2024 |
| VIKING GLOBAL INVESTORS LP | 4.42% | 0.05% | 4,400,000 | - | - | 13,112,000 | Jun 30, 2024 |
| SIMPLIFY ASSET MANAGEMENT INC. | 0.20% | 0.04% | 200,000 | - | - | 596,000 | Jun 30, 2024 |
| MAI CAPITAL MANAGEMENT | 1.32% | 0.04% | 1,318,496 | 186,675 | 16.49% | 3,929,118 | Jun 30, 2024 |
The largest Trevi Therapeutics shareholder by % of total assets is ROSALIND ADVISORS, INC.. The company owns 1.39M shares of Trevi Therapeutics (TRVI), representing 3.19% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ALLY BRIDGE GROUP (NY) LLC | 1.48% | 2.62% | 1,474,926 | 1,474,926 | 100.00% | 4,395,279 | Jun 30, 2024 |
| BLACKROCK INC. | 3.15% | 0.00% | 3,135,115 | 759,406 | 31.97% | 9,342,643 | Jun 30, 2024 |
| LOGOS GLOBAL MANAGEMENT LP | 2.81% | 0.68% | 2,800,000 | 600,000 | 27.27% | 8,344,000 | Jun 30, 2024 |
| ROSALIND ADVISORS, INC. | 1.40% | 3.19% | 1,391,577 | 465,561 | 50.28% | 4,146,899 | Jun 30, 2024 |
| TEJARA CAPITAL LTD | 0.41% | 0.44% | 405,988 | 368,507 | 983.18% | 1,209,844 | Jun 30, 2024 |
| ACUTA CAPITAL PARTNERS, LLC | 0.26% | 0.65% | 260,000 | 260,000 | 100.00% | 774,800 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.15% | 0.00% | 1,146,748 | 248,783 | 27.71% | 3,417,619 | Jun 30, 2024 |
| MAI CAPITAL MANAGEMENT | 1.32% | 0.04% | 1,318,496 | 186,675 | 16.49% | 3,929,118 | Jun 30, 2024 |
| BIOIMPACT CAPITAL LLC | 1.52% | 0.70% | 1,510,174 | 169,214 | 12.62% | 4,500,319 | Jun 30, 2024 |
| VANGUARD GROUP INC | 2.45% | 0.00% | 2,437,451 | 133,803 | 5.81% | 7,263,603 | Jun 30, 2024 |
| STATE STREET CORP | 0.90% | 0.00% | 899,861 | 101,612 | 12.73% | 2,681,586,000 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.19% | 0.01% | 185,481 | 89,000 | 92.25% | 552,733 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.18% | 0.00% | 178,511 | 49,884 | 38.78% | 531,962 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.07% | 0.00% | 72,210 | 49,475 | 217.62% | 214,990 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.15% | 0.00% | 150,918 | 43,211 | 40.12% | 449,736 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.07% | - | 73,193 | 35,219 | 92.75% | 218,115 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.03% | 0.00% | 31,595 | 31,595 | 100.00% | 94,153 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.08% | 0.00% | 75,218 | 23,263 | 44.78% | 224,139 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.04% | - | 44,284 | 22,308 | 101.51% | 131,966 | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.10% | 0.00% | 96,350 | 21,501 | 28.73% | 287,123 | Jun 30, 2024 |
As of Jun 30 2024, Trevi Therapeutics's largest institutional buyer is ALLY BRIDGE GROUP (NY) LLC. The company purchased 1.47M stocks of TRVI, valued at $4.40M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RUBRIC CAPITAL MANAGEMENT LP | 5.05% | 0.39% | 5,026,931 | -537,192 | -9.65% | 14,980,254 | Jun 30, 2024 |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 0.61% | 0.15% | 605,442 | -134,686 | -18.20% | 1,804,217 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.05% | 0.00% | 51,900 | -64,942 | -55.58% | 154,662 | Jun 30, 2024 |
| ATOM INVESTORS LP | - | - | - | -45,736 | -100.00% | - | Jun 30, 2024 |
| SHAY CAPITAL LLC | 0.09% | 0.04% | 88,462 | -25,200 | -22.17% | 263,617 | Jun 30, 2024 |
| UBS GROUP AG | 0.02% | - | 18,009 | -24,109 | -57.24% | 53,667 | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -20,773 | -100.00% | - | Jun 30, 2024 |
| PFS PARTNERS, LLC | 0.08% | 0.15% | 79,000 | -20,000 | -20.20% | 235,420 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | - | - | - | -18,441 | -100.00% | - | Jun 30, 2024 |
| BNP PARIBAS ARBITRAGE, SNC | 0.01% | - | 5,166 | -15,411 | -74.89% | 15,395 | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -15,027 | -100.00% | - | Jun 30, 2024 |
| SG AMERICAS SECURITIES, LLC | - | - | - | -14,592 | -100.00% | - | Jun 30, 2024 |
| AMERIPRISE FINANCIAL INC | 0.01% | - | 14,948 | -6,660 | -30.82% | 44,545 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.32% | 0.00% | 321,102 | -6,590 | -2.01% | 956,884,000 | Jun 30, 2024 |
| CHECKPOINT CAPITAL L.P. | 0.50% | 0.90% | 500,089 | -5,993 | -1.18% | 1,490,265 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 0.01% | - | 13,923 | -3,894 | -21.86% | 41,491 | Jun 30, 2024 |
| METLIFE INVESTMENT MANAGEMENT, LLC | 0.02% | 0.00% | 18,881 | -3,812 | -16.80% | 56,265 | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -2,335 | -100.00% | - | Jun 30, 2024 |
| BARCLAYS PLC | 0.03% | - | 33,915 | -1,280 | -3.64% | 101,000 | Jun 30, 2024 |
| INVESCO LTD. | 0.02% | - | 19,723 | -165 | -0.83% | 58,775 | Jun 30, 2024 |
As of Jun 30 2024, Trevi Therapeutics's biggest institutional seller is RUBRIC CAPITAL MANAGEMENT LP. The company sold -0.54M shares of TRVI, valued at $14.98M.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ALLY BRIDGE GROUP (NY) LLC | 1.48% | 2.62% | 1,474,926 | 1,474,926 | 100.00% | 4,395,279 | Jun 30, 2024 |
| ACUTA CAPITAL PARTNERS, LLC | 0.26% | 0.65% | 260,000 | 260,000 | 100.00% | 774,800 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.03% | 0.00% | 31,595 | 31,595 | 100.00% | 94,153 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.02% | 0.00% | 21,151 | 21,151 | 100.00% | 63,030 | Jun 30, 2024 |
| HSBC HOLDINGS PLC | 0.02% | - | 19,612 | 19,612 | 100.00% | 60,797 | Jun 30, 2024 |
| ALLIANCEBERNSTEIN L.P. | 0.02% | - | 15,440 | 15,440 | 100.00% | 46,011 | Jun 30, 2024 |
Trevi Therapeutics's largest new institutional shareholder by number of shares is ALLY BRIDGE GROUP (NY) LLC, purchased 1.47M shares, valued at $4.40M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ATOM INVESTORS LP | - | - | - | -45,736 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -20,773 | -100.00% | - | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | - | - | - | -18,441 | -100.00% | - | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -15,027 | -100.00% | - | Jun 30, 2024 |
| SG AMERICAS SECURITIES, LLC | - | - | - | -14,592 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -2,335 | -100.00% | - | Jun 30, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | - | - | - | -25 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -6 | -100.00% | - | Jun 30, 2024 |
Trevi Therapeutics's largest sold out institutional shareholder by shares sold is ATOM INVESTORS LP, sold -45.74K shares, valued at -, as of undefined.
Trevi Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| FRANKLIN STRATEGIC SERIES | 0.05% | 405,728 | - | - | Jan 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.04% | 9,226 | - | - | Mar 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.04% | 18,542 | - | - | Mar 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.04% | 83,881 | -115,000 | -57.82% | Mar 28, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.02% | 1,301,455 | - | - | Feb 29, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 6,548 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 67,467 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 2,051,027 | -438,460 | -17.61% | Mar 31, 2024 |
| Simplify Exchange Traded Funds | 0.00% | 200,000 | 200,000 | - | Mar 28, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 107,707 | - | - | Jan 31, 2024 |
| DRIEHAUS MUTUAL FUNDS | 0.00% | 22,499 | - | - | Mar 28, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 361,325 | 21,336 | 6.28% | Feb 29, 2024 |
| Brinker Capital Destinations Trust | 0.00% | 101,038 | - | - | Feb 29, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 3,438 | - | - | Mar 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 29,030 | -2,318 | -7.39% | Mar 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 13,274 | -4,186 | -23.97% | Mar 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,451 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 12,800 | - | - | Mar 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 21,063 | - | - | Feb 29, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 501,693 | - | - | Dec 31, 2023 |
| NORTHERN FUNDS | 0.00% | 20,004 | 2,563 | 14.70% | Mar 28, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 2,746 | 693 | 33.76% | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 1,528,336 | -18,146 | -1.17% | Mar 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 380 | - | - | Dec 31, 2023 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 180,147 | 19,967 | 12.47% | Feb 29, 2024 |
| EQ ADVISORS TRUST | 0.00% | 81,743 | - | - | Mar 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,800 | - | - | Mar 28, 2024 |
| VALIC Co I | 0.00% | 16,176 | 136 | 0.85% | Feb 29, 2024 |
| Dimensional ETF Trust | 0.00% | 24,474 | - | - | Jan 31, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 6,699 | - | - | Jan 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 188 | - | - | Dec 31, 2023 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 6,083 | - | - | Mar 31, 2024 |
| ProFunds | 0.00% | 327 | -27 | -7.63% | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 6,174 | 798 | 14.84% | Feb 29, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 2,218 | - | - | Feb 29, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 25 | - | - | Dec 31, 2023 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 4,490 | - | - | Jan 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 57,709 | - | - | Jan 31, 2024 |
| Brighthouse Funds Trust II | 0.00% | 14,303 | 14,303 | - | Mar 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 35,700 | - | - | Mar 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 4,775 | 40 | 0.84% | Jan 31, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 11,109 | - | - | Jan 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 30,838 | -3,039 | -8.97% | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 13,074 | 12,236 | 1460.14% | Mar 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 16,101 | -1,230 | -7.10% | Mar 31, 2024 |
| Bridge Builder Trust | 0.00% | 16,159 | - | - | Mar 31, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 5,182 | - | - | Mar 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 5,804 | - | - | Jan 31, 2024 |
Trevi Therapeutics's largest mutual fund holder by % of total assets is "FRANKLIN STRATEGIC SERIES", owning 405.73K shares, compromising 0.05% of its total assets.
Trevi Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 29 | -64.20% |
| 31 Mar, 24 | 81 | 24.62% |
| 31 Dec, 23 | 65 | 18.18% |
| 30 Sep, 23 | 55 | - |
| 30 Jun, 23 | 55 | 48.65% |
| 31 Mar, 23 | 37 | -2.63% |
| 31 Dec, 22 | 38 | - |
| 30 Sep, 22 | 38 | 22.58% |
| 30 Jun, 22 | 31 | 47.62% |
| 31 Mar, 22 | 21 | 31.25% |
| 31 Dec, 21 | 16 | 6.67% |
| 30 Sep, 21 | 15 | - |
| 30 Jun, 21 | 15 | -11.76% |
| 31 Mar, 21 | 17 | - |
| 31 Dec, 20 | 17 | 21.43% |
| 30 Sep, 20 | 14 | 16.67% |
| 30 Jun, 20 | 12 | -33.33% |
| 31 Mar, 20 | 18 | 5.88% |
| 31 Dec, 19 | 17 | -5.56% |
| 30 Sep, 19 | 18 | - |
| 30 Jun, 19 | 18 | - |
As of 30 Jun 24, 29 institutions are holding Trevi Therapeutics's shares, representing a decrease of -64.20% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 5,956,347 | -88.45% |
| 31 Mar, 24 | 51,561,502 | -1.29% |
| 31 Dec, 23 | 52,235,708 | 7.30% |
| 30 Sep, 23 | 48,682,678 | -0.29% |
| 30 Jun, 23 | 48,822,080 | 12.33% |
| 31 Mar, 23 | 43,462,507 | 0.64% |
| 31 Dec, 22 | 43,185,947 | -5.65% |
| 30 Sep, 22 | 45,771,831 | 59.20% |
| 30 Jun, 22 | 28,751,331 | 302.12% |
| 31 Mar, 22 | 7,149,893 | -45.71% |
| 31 Dec, 21 | 13,170,032 | 5.80% |
| 30 Sep, 21 | 12,448,249 | -0.24% |
| 30 Jun, 21 | 12,478,497 | -4.95% |
| 31 Mar, 21 | 13,128,768 | 0.93% |
| 31 Dec, 20 | 13,007,586 | -1.93% |
| 30 Sep, 20 | 13,263,696 | -0.83% |
| 30 Jun, 20 | 13,374,829 | -4.23% |
| 31 Mar, 20 | 13,965,026 | -1.52% |
| 31 Dec, 19 | 14,180,144 | 0.46% |
| 30 Sep, 19 | 14,115,682 | -0.40% |
| 30 Jun, 19 | 14,171,891 | - |
Trevi Therapeutics (TRVI) has 5.96M shares outstanding as of 30 Jun 24, down -88.45% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 5.99% | 0.22% |
| 31 Mar, 24 | 52.06% | 1.88% |
| 31 Dec, 23 | 52.59% | 2.16% |
| 30 Sep, 23 | 49.32% | 2.01% |
| 30 Jun, 23 | 49.51% | 2.55% |
| 31 Mar, 23 | 44.07% | 0.98% |
| 31 Dec, 22 | 66.91% | 1.52% |
| 30 Sep, 22 | 66.43% | 2.85% |
| 30 Jun, 22 | 48.29% | 8.96% |
| 31 Mar, 22 | 23.21% | 0.70% |
| 31 Dec, 21 | 57.66% | 1.74% |
| 30 Sep, 21 | 57.61% | 1.50% |
| 30 Jun, 21 | 62.01% | 1.36% |
| 31 Mar, 21 | 67.61% | 1.37% |
| 31 Dec, 20 | 70.13% | 1.31% |
| 30 Sep, 20 | 73.14% | 1.30% |
| 30 Jun, 20 | 74.99% | 1.22% |
| 31 Mar, 20 | 78.30% | 1.24% |
| 31 Dec, 19 | 79.51% | 1.27% |
| 30 Sep, 19 | 79.15% | 1.25% |
| 30 Jun, 19 | 79.46% | - |
As of 30 Jun 24, Trevi Therapeutics is held by 5.99% institutional shareholders, representing a 0.22% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 14 | -62.16% |
| 31 Mar, 24 | 37 | -2.63% |
| 31 Dec, 23 | 38 | 100.00% |
| 30 Sep, 23 | 19 | -51.28% |
| 30 Jun, 23 | 39 | 178.57% |
| 31 Mar, 23 | 14 | -22.22% |
| 31 Dec, 22 | 18 | -25.00% |
| 30 Sep, 22 | 24 | - |
| 30 Jun, 22 | 24 | 100.00% |
| 31 Mar, 22 | 12 | 20.00% |
| 31 Dec, 21 | 10 | 150.00% |
| 30 Sep, 21 | 4 | -20.00% |
| 30 Jun, 21 | 5 | -28.57% |
| 31 Mar, 21 | 7 | - |
| 31 Dec, 20 | 7 | 40.00% |
| 30 Sep, 20 | 5 | -16.67% |
| 30 Jun, 20 | 6 | 20.00% |
| 31 Mar, 20 | 5 | 25.00% |
| 31 Dec, 19 | 4 | -33.33% |
| 30 Sep, 19 | 6 | -66.67% |
| 30 Jun, 19 | 18 | - |
14 institutional shareholders have increased their position in TRVI stock as of 30 Jun 24 compared to 37 in the previous quarter (a -62.16% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 3 | -88.89% |
| 31 Mar, 24 | 27 | 92.86% |
| 31 Dec, 23 | 14 | -17.65% |
| 30 Sep, 23 | 17 | 142.86% |
| 30 Jun, 23 | 7 | -12.50% |
| 31 Mar, 23 | 8 | - |
| 31 Dec, 22 | 8 | -11.11% |
| 30 Sep, 22 | 9 | 80.00% |
| 30 Jun, 22 | 5 | - |
| 31 Mar, 22 | 5 | 400.00% |
| 31 Dec, 21 | 1 | -66.67% |
| 30 Sep, 21 | 3 | - |
| 30 Jun, 21 | 3 | 50.00% |
| 31 Mar, 21 | 2 | - |
| 31 Dec, 20 | 2 | -33.33% |
| 30 Sep, 20 | 3 | - |
| 30 Jun, 20 | 3 | -25.00% |
| 31 Mar, 20 | 4 | - |
| 31 Dec, 19 | 4 | -20.00% |
| 30 Sep, 19 | 5 | - |
| 30 Jun, 19 | - | - |
3 institutional shareholders have reduced their position in TRVI stock as of 30 Jun 24 compared to 27 in the previous quarter (a -88.89% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 29 | -64.20% | 5,956,347 | -88.45% | 5.99% | 0.22% | 14 | -62.16% | 3 | -88.89% |
| 31 Mar, 24 | 81 | 24.62% | 51,561,502 | -1.29% | 52.06% | 1.88% | 37 | -2.63% | 27 | 92.86% |
| 31 Dec, 23 | 65 | 18.18% | 52,235,708 | 7.30% | 52.59% | 2.16% | 38 | 100.00% | 14 | -17.65% |
| 30 Sep, 23 | 55 | - | 48,682,678 | -0.29% | 49.32% | 2.01% | 19 | -51.28% | 17 | 142.86% |
| 30 Jun, 23 | 55 | 48.65% | 48,822,080 | 12.33% | 49.51% | 2.55% | 39 | 178.57% | 7 | -12.50% |
| 31 Mar, 23 | 37 | -2.63% | 43,462,507 | 0.64% | 44.07% | 0.98% | 14 | -22.22% | 8 | - |
| 31 Dec, 22 | 38 | - | 43,185,947 | -5.65% | 66.91% | 1.52% | 18 | -25.00% | 8 | -11.11% |
| 30 Sep, 22 | 38 | 22.58% | 45,771,831 | 59.20% | 66.43% | 2.85% | 24 | - | 9 | 80.00% |
| 30 Jun, 22 | 31 | 47.62% | 28,751,331 | 302.12% | 48.29% | 8.96% | 24 | 100.00% | 5 | - |
| 31 Mar, 22 | 21 | 31.25% | 7,149,893 | -45.71% | 23.21% | 0.70% | 12 | 20.00% | 5 | 400.00% |
| 31 Dec, 21 | 16 | 6.67% | 13,170,032 | 5.80% | 57.66% | 1.74% | 10 | 150.00% | 1 | -66.67% |
| 30 Sep, 21 | 15 | - | 12,448,249 | -0.24% | 57.61% | 1.50% | 4 | -20.00% | 3 | - |
| 30 Jun, 21 | 15 | -11.76% | 12,478,497 | -4.95% | 62.01% | 1.36% | 5 | -28.57% | 3 | 50.00% |
| 31 Mar, 21 | 17 | - | 13,128,768 | 0.93% | 67.61% | 1.37% | 7 | - | 2 | - |
| 31 Dec, 20 | 17 | 21.43% | 13,007,586 | -1.93% | 70.13% | 1.31% | 7 | 40.00% | 2 | -33.33% |
| 30 Sep, 20 | 14 | 16.67% | 13,263,696 | -0.83% | 73.14% | 1.30% | 5 | -16.67% | 3 | - |
| 30 Jun, 20 | 12 | -33.33% | 13,374,829 | -4.23% | 74.99% | 1.22% | 6 | 20.00% | 3 | -25.00% |
| 31 Mar, 20 | 18 | 5.88% | 13,965,026 | -1.52% | 78.30% | 1.24% | 5 | 25.00% | 4 | - |
| 31 Dec, 19 | 17 | -5.56% | 14,180,144 | 0.46% | 79.51% | 1.27% | 4 | -33.33% | 4 | -20.00% |
| 30 Sep, 19 | 18 | - | 14,115,682 | -0.40% | 79.15% | 1.25% | 6 | -66.67% | 5 | - |
| 30 Jun, 19 | 18 | - | 14,171,891 | - | 79.46% | - | 18 | - | - | - |
Trevi Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Trevi Therapeutics's stock was made by SCIASCIA THOMAS on Aug 16 2024, selling 12,745 shares at $2.79 per share (valued at $35.51K).
Trevi Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 3 | 6 | 50.00% |
| Q2 2024 | 10 | 8 | 125.00% |
| Q1 2024 | 6 | - | - |
| Q4 2023 | 1 | 2 | 50.00% |
| Q3 2023 | 3 | 6 | 50.00% |
| Q2 2023 | 10 | 7 | 142.86% |
| Q1 2023 | 8 | 9 | 88.89% |
| Q4 2022 | 1 | - | - |
| Q3 2022 | 2 | 3 | 66.67% |
| Q2 2022 | 43 | 8 | 537.50% |
| Q1 2022 | 8 | - | - |
| Q4 2021 | 27 | - | - |
| Q3 2021 | 1 | - | - |
| Q2 2021 | 7 | - | - |
| Q1 2021 | 5 | - | - |
| Q2 2020 | 16 | 22 | 72.73% |
| Q1 2020 | 7 | - | - |
| Q2 2019 | 79 | 99 | 79.80% |
3 total buy trades, and 6 total sell trades (buy/sell ratio of 0.50%) were made by Trevi Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 3 | - |
| Q2 2024 | - | 4 | - |
| Q1 2024 | - | - | - |
| Q4 2023 | - | 1 | - |
| Q3 2023 | - | 3 | - |
| Q2 2023 | - | 3 | - |
| Q1 2023 | - | 2 | - |
| Q4 2022 | - | - | - |
| Q3 2022 | - | 3 | - |
| Q2 2022 | 23 | 8 | 287.50% |
| Q1 2022 | - | - | - |
| Q4 2021 | 27 | - | - |
| Q3 2021 | - | - | - |
| Q2 2021 | - | - | - |
| Q1 2021 | - | - | - |
| Q2 2020 | - | 10 | - |
| Q1 2020 | - | - | - |
| Q2 2019 | 35 | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 3 open market sell trades of Trevi Therapeutics's stocks.
Trevi Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| CUE | Cue Biopharma, Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| SEER | Seer, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| BCAB | BioAtla, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| SPRO | Spero Therapeutics, Inc. |
| SQZ | SQZ Biotechnologies Company |
| BOLT | Bolt Biotherapeutics, Inc. |
| ORIC | ORIC Pharmaceuticals, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| RZLT | Rezolute, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| TARA | Protara Therapeutics, Inc. |
| NLTX | Neurogene Inc. |
| CHRS | Coherus BioSciences, Inc. |
| LIFE | aTyr Pharma, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
TRVI Ownership FAQ
Who Owns Trevi Therapeutics?
Trevi Therapeutics is owned by institutional shareholders (5.99%), insiders (1.25%), and public (92.77%). The largest institutional shareholder of Trevi Therapeutics is NEA MANAGEMENT COMPANY, LLC (11.43% of total shares) and the top mutual fund owner is FRANKLIN STRATEGIC SERIES (0.05% of total shares).
Who are the major institutional shareholders of Trevi Therapeutics?
Trevi Therapeutics's major institutional shareholders are NEA MANAGEMENT COMPANY, LLC, FRAZIER LIFE SCIENCES MANAGEMENT, L.P., RUBRIC CAPITAL MANAGEMENT LP, VIKING GLOBAL INVESTORS LP, and VR ADVISER, LLC. The top five shareholders own together 31.75% of the company's share outstanding.
How many Trevi Therapeutics shareholders are there?
As of Jun 2024, there are 29 institutional shareholders of Trevi Therapeutics.
What percentage of Trevi Therapeutics is owned by NEA MANAGEMENT COMPANY, LLC?
NEA MANAGEMENT COMPANY, LLC owns 11.37M shares of Trevi Therapeutics, representing 11.43% of the company's total shares outstanding, valued at $33.88M (as of Jun 2024).
What percentage of Trevi Therapeutics is owned by FRAZIER LIFE SCIENCES MANAGEMENT, L.P?
As of Jun 2024, FRAZIER LIFE SCIENCES MANAGEMENT, L.P holds 7.38M shares of Trevi Therapeutics (TRVI), compromising 7.42% of the company, valued at $22M.
What percentage of Trevi Therapeutics is owned by RUBRIC CAPITAL MANAGEMENT LP?
RUBRIC CAPITAL MANAGEMENT LP is the third largest holder of Trevi Therapeutics. The company owns 5.03M of the company's shares outstanding (worth $14.98M).